Effect of mild hepatic impairment on the pharmacokinetics of pelacarsen

被引：0
|
作者：
Yan, Jing-He
Taylor, Amanda
Clough, Timothy
Burmeister-Getz, Elise
Pazdirkova, Marketa
Russo, Cesare
机构：
来源：
CIRCULATION | 2024年 / 150卷
关键词：
D O I：
10.1161/circ.150.suppl_1.4135023
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4135023
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Effect of hepatic impairment on tepotinib pharmacokinetics
    Marbury, T.
    Yalkinoglu, Oe.
    Becker, A.
    Krebs-Brown, A.
    Bytyqi, A.
    Port, A.
    Strotmann, R.
    ANNALS OF ONCOLOGY, 2021, 32 : S987 - S987
  • [22] Effect of hepatic impairment on the pharmacokinetics of zolmitriptan
    Dixon, R
    French, S
    Kemp, J
    Sellers, M
    Leclerc, T
    Delvaux, M
    Rautureau, J
    JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (08): : 694 - 701
  • [23] EFFECT OF HEPATIC IMPAIRMENT ON RECAINAM PHARMACOKINETICS
    WEIDLER, DJ
    WALLACE, D
    ZIMMERMAN, J
    CEVALLOS, WH
    GALLO, BV
    CHIANG, ST
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (02) : 180 - 180
  • [24] EFFECT OF HEPATIC IMPAIRMENT ON BITOPERTIN PHARMACOKINETICS
    Pizzagalli, F.
    Denot, C.
    Homery, M.
    Kobalava, Z.
    Martin-Facklam, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S103 - S103
  • [25] The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib
    Joseph Piscitelli
    Joseph Chen
    Robert R. LaBadie
    Joanne Salageanu
    Chin-Hee Chung
    Weiwei Tan
    Clinical Drug Investigation, 2022, 42 : 221 - 235
  • [26] THE EFFECT OF MILD TO MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF TASOCITINIB (CP-690,550)
    Lawendy, N.
    Chan, G.
    Wang, R.
    Lamba, M.
    Krishnaswami, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S93 - S94
  • [27] Mild to Moderate Hepatic Impairment Has No Effect on the Single Dose Pharmacokinetics of Alisporivir (ALV)
    Kovacs, Steven J.
    Ke, June
    Praestgaard, Jens
    Barve, Avantika
    Zhang, Jie
    Maietta, Robert
    Sunkara, Gangadhar
    Stein, Daniel S.
    GASTROENTEROLOGY, 2013, 144 (05) : S977 - S977
  • [28] Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten
    Xu, Donghong
    Lutz, Justin D.
    Divanji, Punag
    Li, Jianlin
    Benattia, Youcef
    Griffith, Adrienne
    Heitner, Stephen B.
    Kupfer, Stuart
    German, Polina
    CLINICAL PHARMACOKINETICS, 2025, : 397 - 406
  • [29] Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment
    Zimmerman, JJ
    Lasseter, KC
    Lim, HK
    Harper, D
    Dilzer, SC
    Parker, V
    Matschke, K
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (12): : 1368 - 1372
  • [30] Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
    Frost, Charles E.
    Ly, Van
    Garonzik, Samira M.
    DRUGS IN R&D, 2021, 21 (04) : 375 - 384
12345